NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- Stock-based compensation, 2025
- $218M
- YoY, 2025
- +11.5%
- 5-year CAGR
- +16.9%
- 10-year CAGR
- +22.6%
Stock-based compensation
Stock-based compensation by fiscal year
| Period | Stock comp | YoY |
|---|---|---|
| 2025 | $218M | +11.5% |
| 2024 | $196M | +0.6% |
| 2023 | $194M | +12.2% |
| 2022 | $173M | +29.0% |
| 2021 | $134M | +34.2% |
| 2020 | $100M | +32.8% |
| 2019 | $75M | +29.6% |
| 2018 | $58M | +36.6% |
| 2017 | $43M | +49.4% |
| 2016 | $28M | +0.3% |
| 2015 | $28M | +173.5% |
| 2014 | $10M | +52.3% |
| 2013 | $6.8M | +24.5% |
| 2012 | $5.5M | +87.8% |
| 2011 | $2.9M | −6.9% |
| 2010 | $3.1M | −43.4% |
| 2009 | $5.5M | — |